RESÚMENES DEL XLII CONGRESO DE LA SOCIEDAD ESPAÑOLA DE NEFROLOGÍA Y VII IBEROAMERICANO DE NEFROLOGÍA
RESÚMENES DEL XLII CONGRESO DE LA SOCIEDAD ESPAÑOLA DE NEFROLOGÍA Y VII IBEROAMERICANO DE NEFROLOGÍA
![Optimized ACE2 decoys neutralize antibody-resistant SARS-CoV-2 variants through functional receptor mimicry and treat infection in vivo | Science Advances Optimized ACE2 decoys neutralize antibody-resistant SARS-CoV-2 variants through functional receptor mimicry and treat infection in vivo | Science Advances](https://www.science.org/cms/10.1126/sciadv.abq6527/asset/4169c14e-2075-482d-9852-59f2eac1dd6a/assets/images/large/sciadv.abq6527-f1.jpg)
Optimized ACE2 decoys neutralize antibody-resistant SARS-CoV-2 variants through functional receptor mimicry and treat infection in vivo | Science Advances
![Monoclonal antibodies targeting two immunodominant epitopes on the Spike protein neutralize emerging SARS-CoV-2 variants of concern - eBioMedicine Monoclonal antibodies targeting two immunodominant epitopes on the Spike protein neutralize emerging SARS-CoV-2 variants of concern - eBioMedicine](https://www.thelancet.com/cms/asset/1c286603-5a7d-4bb9-a109-6d1568197364/gr1.jpg)
Monoclonal antibodies targeting two immunodominant epitopes on the Spike protein neutralize emerging SARS-CoV-2 variants of concern - eBioMedicine
![Emergence of the E484K mutation in SARS-COV-2-infected immunocompromised patients treated with bamlanivimab in Germany - The Lancet Regional Health – Europe Emergence of the E484K mutation in SARS-COV-2-infected immunocompromised patients treated with bamlanivimab in Germany - The Lancet Regional Health – Europe](https://www.thelancet.com/cms/attachment/ff3b1786-68d5-4dd4-bc5d-74d2ac3babc4/gr1_lrg.jpg)
Emergence of the E484K mutation in SARS-COV-2-infected immunocompromised patients treated with bamlanivimab in Germany - The Lancet Regional Health – Europe
![Potent neutralizing nanobodies resist convergent circulating variants of SARS-CoV-2 by targeting diverse and conserved epitopes | Nature Communications Potent neutralizing nanobodies resist convergent circulating variants of SARS-CoV-2 by targeting diverse and conserved epitopes | Nature Communications](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41467-021-24963-3/MediaObjects/41467_2021_24963_Fig1_HTML.png)
Potent neutralizing nanobodies resist convergent circulating variants of SARS-CoV-2 by targeting diverse and conserved epitopes | Nature Communications
![Molecular characteristics, immune evasion, and impact of SARS-CoV-2 variants | Signal Transduction and Targeted Therapy Molecular characteristics, immune evasion, and impact of SARS-CoV-2 variants | Signal Transduction and Targeted Therapy](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41392-022-01039-2/MediaObjects/41392_2022_1039_Fig1_HTML.png)
Molecular characteristics, immune evasion, and impact of SARS-CoV-2 variants | Signal Transduction and Targeted Therapy
Human ACE2 Peptide-Attached Plasmonic-Magnetic Heterostructure for Magnetic Separation, Surface Enhanced Raman Spectroscopy Identification, and Inhibition of Different Variants of SARS-CoV-2 Infections | ACS Applied Bio Materials
![Advances in Nanomaterial-Based Platforms to Combat COVID-19: Diagnostics, Preventions, Therapeutics, and Vaccine Developments | ACS Applied Bio Materials Advances in Nanomaterial-Based Platforms to Combat COVID-19: Diagnostics, Preventions, Therapeutics, and Vaccine Developments | ACS Applied Bio Materials](https://pubs.acs.org/cms/10.1021/acsabm.2c00123/asset/images/medium/mt2c00123_0016.gif)
Advances in Nanomaterial-Based Platforms to Combat COVID-19: Diagnostics, Preventions, Therapeutics, and Vaccine Developments | ACS Applied Bio Materials
![Engineered extracellular vesicles directed to the spike protein inhibit SARS-CoV-2: Molecular Therapy - Methods & Clinical Development Engineered extracellular vesicles directed to the spike protein inhibit SARS-CoV-2: Molecular Therapy - Methods & Clinical Development](https://www.cell.com/cms/attachment/6ca7887f-d867-4d10-9e0e-bbea705c83a6/fx1_lrg.jpg)